Related Experiment Video
Updated: May 14, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Is rosmarinic acid underestimated as an experimental cardiovascular drug?
Luciana Garros Ferreira1, Andrea Carla Celotto, Verena Kise Capellini
1Postgraduate Program in Medical Surgical Clinic, Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil.
Purpose:
The rationale of the present review is to analize the activity of Rosmarinus officinalis in the the cardiovascular system
Methods:
A MEDLINE database search (from January 1970 to December 2011) using only rosmarinic acid as searched term.
Results:
The references search revealed 509 references about rosmarinic acid in 40 years (the first reference is from 1970). There is a powerful prevalence of antioxidant and cancer studies. Other diseases are few cited, as inflammation, brain (Alzheimer and Parkinson disease) and, memory; allergy; diabetes; atherosclerosis, and; hypertension. It is necessary to consider the complete absence of studies on coronary artery disease, myocardial ischemia, heart failure or ischemia/reperfusion injury.
Conclusion:
Rosmarinic acid is underestimated as an experimental cardiovascular drug and deserves more attention.
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
